Gossamer Bio: Risk Prevails Over Future Benefit [Seeking Alpha]
Gossamer Bio, Inc. (GOSS)
Last gossamer bio, inc. earnings: 3/24 07:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Gossamer Bio: Risk Prevails Over Future Benefit I decided to finalize my bearish thesis on Gossamer Bio ( GOSS Gossamer Bio, Inc. is San Diego based biotech start-up. The lead drug candidate of the company, GB001 Phase-2b The company must first show the effectiveness of its drug candidate, and then, if it succeeds, prove the advantages of its medicine over other competing products on the market. I am skeptical of this probability. Next, I will explain the reasons for my skepticism. Before diving into the details, let's look through asthma, its forms, and the current standard of care. Asthma There is no complete cure for asthma, but treatment methods help patients with asthma lead an active lifestyle. There are several types Allergic asthma Nonallergic Asthma Adult-Onset Asthma: Exercise-Induced Bronchoconstriction Occupational Asthma: Asthma-COPD Overlap: Depending on the severity of asthma, patients are usually prescribed There is also a rare form of asthma called Eosinophilic Asthma
Show less
Read more
Impact Snapshot
Event Time:
GOSS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOSS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOSS alerts
High impacting Gossamer Bio, Inc. news events
Weekly update
A roundup of the hottest topics
GOSS
News
- Gossamer Bio Decline Means Insider Profits Down To US$17k [Yahoo! Finance]Yahoo! Finance
- Gossamer Bio, Inc. (NASDAQ: GOSS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.MarketBeat
- Gossamer Bio, Inc. (NASDAQ: GOSS) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $15.00 price target on the stock.MarketBeat
- Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of DirectorsBusiness Wire
GOSS
Earnings
- 11/9/23 - Miss
GOSS
Sec Filings
- 4/26/24 - Form ARS
- 4/24/24 - Form DEFA14A
- 4/24/24 - Form DEF
- GOSS's page on the SEC website